$NVS has been mentioned 36 times over the past 12 months by two distinct FinTwit voices, with the discussion beginning on September 9, 2025. Jacob Plieth (@jacobplieth) has driven the majority of the conversation with 30 mentions, while Adam Feuerstein (@adamfeuerstein) contributed 12 mentions. The biotech category dominated discussion of Novartis during this period.

Recent activity in June and July 2026 centered on Novartis's acquisition of Myricx Bio for $1.1 billion, with @jacobplieth providing technical details about the acquired company's N-myristoyltransferase inhibitor ADC payload technology. Discussion also included speculation about executive travel and strategic positioning, with CEO Vas Narasimhan appearing at healthcare events in San Francisco.